Olistico Wealth LLC Lowers Stock Holdings in Eli Lilly and Company $LLY

Olistico Wealth LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 29.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,504 shares of the company’s stock after selling 1,068 shares during the quarter. Eli Lilly and Company makes up 1.1% of Olistico Wealth LLC’s holdings, making the stock its 19th largest position. Olistico Wealth LLC’s holdings in Eli Lilly and Company were worth $1,952,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Carolina Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 40.0% in the second quarter. Carolina Wealth Advisors LLC now owns 1,312 shares of the company’s stock valued at $1,023,000 after acquiring an additional 375 shares in the last quarter. MBL Wealth LLC lifted its position in shares of Eli Lilly and Company by 3.4% in the second quarter. MBL Wealth LLC now owns 1,611 shares of the company’s stock valued at $1,256,000 after acquiring an additional 53 shares in the last quarter. Wealthcare Capital Partners LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $256,000. Hill Island Financial LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $341,000. Finally, Ergawealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 4.0% in the second quarter. Ergawealth Advisors Inc. now owns 626 shares of the company’s stock valued at $488,000 after acquiring an additional 24 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 over the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. UBS Group decreased their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. HSBC raised their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $938.94.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $840.46 on Friday. The stock has a 50 day moving average price of $734.60 and a 200 day moving average price of $765.98. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $795.47 billion, a PE ratio of 54.93, a P/E/G ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.